<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>What's new in gastroenterology and hepatology</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">What's new in gastroenterology and hepatology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">What's new in gastroenterology and hepatology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne C Travis, MD, MSc, FACG, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p>The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.</p><p class="headingAnchor" id="H79_143087"><span class="h1">ENDOSCOPY</span></p><p class="headingAnchor" id="H143087"><span class="h2">Motorized spiral enteroscopy for evaluating small bowel disorders (October 2023)</span></p><p>Device-assisted enteroscopy facilitates direct access to the small bowel, but studies on motorized spiral enteroscopy are limited. In a trial comparing motorized spiral enteroscopy with single balloon enteroscopy in 110 adults with suspected small bowel disorders, rates of complete small bowel examination were higher with motorized spiral enteroscopy (71 versus 11 percent) [<a href="#rid1">1</a>]. Motorized spiral enteroscopy also resulted in higher diagnostic yield (80 versus 62 percent) and shorter mean procedure times (58 versus 114 minutes). No major adverse events occurred in either group. These data show promise, but further studies on safety are needed before performing motorized spiral enteroscopy routinely in clinical practice. In addition, its use may be limited by equipment availability and endoscopic expertise. (See  <a class="medical medical_review" href="/z/d/html/2652.html" rel="external">"Overview of deep small bowel enteroscopy", section on 'Motorized spiral enteroscopy'</a>.)</p><p class="headingAnchor" id="H80_142938"><span class="h1">ESOPHAGEAL AND GASTRIC DISEASE</span></p><p class="headingAnchor" id="H142938"><span class="h2">Rifabutin triple therapy for Helicobacter pylori (October 2023)</span></p><p>Management of patients who have failed multiple antibiotic regimens for <em>Helicobacter pylori</em> is an increasingly frequent challenge. In a randomized trial in which 364 subjects with <em>H. pylori</em> who failed at least two prior treatments were assigned to <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a> triple therapy or bismuth quadruple therapy for 14 days, <em>H. pylori</em> eradication rates were similar in both groups [<a href="#rid2">2</a>]. However, the rifabutin group had a higher compliance rate and a lower rate of adverse effects. This trial supports current guidelines and our recommendation to use rifabutin triple therapy as a salvage treatment for <em>H. pylori. </em>(See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults", section on 'Salvage regimens'</a>.)</p><p class="headingAnchor" id="H81_142451"><span class="h1">HEPATOLOGY</span></p><p class="headingAnchor" id="H143883"><span class="h2">Mortality risk in alcohol-associated liver disease (January 2024)</span></p><p>Few studies have reported the long-term outcomes of patients with alcohol-associated liver disease (ALD). In a national registry study including over 23,000 patients with ALD diagnosed at median age 58 years, 67 percent died during &gt;100,000 person-years of follow-up and liver disease was the primary cause of death in 45 percent [<a href="#rid3">3</a>]. The 5- and 10-year mortality rates due to liver disease were 26 and 31 percent, respectively. These data emphasize the importance of treating patients with alcohol use disorder and may inform strategies to prevent liver-related mortality in those with ALD. (See  <a class="medical medical_review" href="/z/d/html/3611.html" rel="external">"Management of alcohol-associated steatosis and alcohol-associated cirrhosis", section on 'Mortality'</a>.)</p><p class="headingAnchor" id="H143131"><span class="h2">Model for End-stage Liver Disease (MELD) 3.0 for liver transplantation (October 2023, Modified December 2023)</span></p><p>The Model for End-stage Liver Disease (MELD) score is used to allocate livers for transplantation. Recently, the Organ Procurement and Transplantation Network implemented an updated score, MELD 3.0, for prioritizing liver transplantation candidates who are ages 12 and older [<a href="#rid4">4</a>]. MELD 3.0 includes variables from the original model (ie, serum bilirubin, serum creatinine, and international normalized ratio) in addition to other inputs (ie, serum sodium, patient sex, and serum albumin) and a lower creatinine ceiling. Goals of using MELD 3.0 include reducing overall waitlist mortality and improving access for female liver transplant candidates. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'MELD 3.0'</a>. and  <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'MELD 3.0'</a>.)</p><p class="headingAnchor" id="H143306"><span class="h2">Paracentesis for hospitalized patients with cirrhosis and ascites (November 2023)</span></p><p>Patients with cirrhosis complicated by ascites are at risk for spontaneous bacterial peritonitis and other complications. However, the magnitude of risk associated with deferring diagnostic paracentesis in such patients when they are hospitalized is uncertain. In a large database study comparing late (ie, ≥24 hours) or no paracentesis with early paracentesis in hospitalized patients with ascites, late paracentesis or no paracentesis was associated with higher risk of acute kidney injury (odds ratio [OR] 2.2 and 1.3, respectively) and inpatient mortality (OR 1.5 and 1.4, respectively) [<a href="#rid5">5</a>]. These data support performing diagnostic paracentesis within 24 hours of hospital admission, which is consistent with our practice. (See  <a class="medical medical_review" href="/z/d/html/16203.html" rel="external">"Diagnostic and therapeutic abdominal paracentesis", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H142408"><span class="h2">Sugar-sweetened beverages and risk of liver cancer (September 2023)</span></p><p>There is interest in evaluating the impact of sugar-sweetened beverages (such as regular sodas and fruit drinks) on the risk of developing liver cancer. In an observational study of almost 99,000 postmenopausal females, higher intake of sugar-sweetened beverages (one or more servings per day) was associated with an increased risk of developing liver cancer (hazard ratio 1.85) relative to less frequent consumption (three or less servings per month) [<a href="#rid6">6</a>]. These findings support the importance of limiting or avoiding sugar-sweetened beverages as part of a healthy diet for adults and for cancer prevention. (See  <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma", section on 'Dietary factors'</a>.)</p><p class="headingAnchor" id="H142451"><span class="h2">Gene therapy for Crigler-Najjar syndrome (September 2023)</span></p><p>Gene therapy for Crigler-Najjar syndrome is directed at restoring sufficient <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F191740&amp;token=tEpDslnpc0F0kICl%2Fz7sFQdsXnRDd5WxpnJNX2h2G8P2L1%2Fe1eNlVntKQmsm%2B1Ie&amp;TOPIC_ID=8351" target="_blank">UGT1A1</a> activity to maintain serum bilirubin in a safe range. In an open-label study of five young adults with Crigler-Najjar syndrome and severe hyperbilirubinemia managed with daily phototherapy (two with adjunctive <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>), gene therapy was administered at one of two doses [<a href="#rid7">7</a>]. For the three participants in the high-dose cohort, the mean total bilirubin concentrations declined from 20.5 mg/dL (351 micromol/L) with phototherapy to 8.7 mg/dL (149 micromol/L) without phototherapy by 80 weeks. There were transient increases in liver enzymes, managed with immunosuppressive therapy, and no serious adverse events. Further studies are needed to determine the indications, optimal protocol, and long-term efficacy and safety of gene therapy. (See  <a class="medical medical_review" href="/z/d/html/3569.html" rel="external">"Crigler-Najjar syndrome", section on 'Investigational therapies'</a>.)</p><p class="headingAnchor" id="H83_143329"><span class="h1">PANCREATIC AND BILIARY DISEASE</span></p><p class="headingAnchor" id="H143156"><span class="h2">Risk of pancreatic cancer in stable intraductal papillary mucinous neoplasms (November 2023)</span></p><p>The optimal duration of pancreatic cancer surveillance in patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) is unclear. In a study of over 3800 such patients without worrisome features (WFs) or high-risk stigmata (HRS), 42 percent had BD-IPMNs that remained stable in size and did not develop WF/HRS for at least five years [<a href="#rid8">8</a>]. Within this group, patients ≥75 years with cysts &lt;30 mm and those ≥65 years with cysts &lt;15 mm had a standardized incidence ratio for pancreatic cancer comparable to the general population and low disease-specific mortality. These data suggest that this subgroup may be able to discontinue pancreatic cancer surveillance; however, further studies are needed to validate these results. (See  <a class="medical medical_review" href="/z/d/html/5632.html" rel="external">"Intraductal papillary mucinous neoplasm of the pancreas (IPMN): Pathophysiology and clinical manifestations", section on 'Pancreatic malignancy'</a>.)</p><p class="headingAnchor" id="H143329"><span class="h2">Microscopic colitis and acute pancreatitis (November 2023)</span></p><p>Microscopic colitis has been associated with several other conditions. In a recent population-based study including &gt;12,000 patients with microscopic colitis, these individuals had a twofold increased risk for acute pancreatitis unrelated to gallstones but no increase in gallstone-related acute pancreatitis compared with matched controls [<a href="#rid9">9</a>]. The increased risk persisted for more than 10 years after diagnosis. Whether the increase in acute pancreatitis was due to active disease or a side effect of <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> is unclear. Further studies are needed to evaluate this association. (See  <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Associated conditions'</a>.)</p><p class="headingAnchor" id="H143320"><span class="h2">Clinical practice update on exocrine pancreatic insufficiency (November 2023)</span></p><p>The American Gastroenterological Association (AGA) recently published best practice advice on exocrine pancreatic insufficiency (EPI) [<a href="#rid10">10</a>]. The AGA Clinical Practice Update advises considering a diagnosis of EPI in individuals with moderate-risk clinical conditions (eg, celiac disease, previous intestinal surgery, longstanding diabetes mellitus, Zollinger-Ellison syndrome). It emphasizes the importance of testing for EPI in patients with nonspecific symptoms and cautions against relying on a response to an empiric trial of pancreatic enzymes to diagnose EPI as this may be due to a placebo effect. Our approach is consistent with this guidance. (See  <a class="medical medical_review" href="/z/d/html/4779.html" rel="external">"Exocrine pancreatic insufficiency", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H84_142039"><span class="h1">SMALL BOWEL AND COLONIC DISEASE</span></p><p class="headingAnchor" id="H142422"><span class="h2">Mirikizumab for moderate to severe ulcerative colitis (August 2023, Modified January 2024)</span></p><p>Therapeutic options for adults with moderate to severe ulcerative colitis (UC) are expanding. In an induction trial comparing <a class="drug drug_general" data-topicid="143211" href="/z/d/drug information/143211.html" rel="external">mirikizumab</a> (a monoclonal antibody that targets the p19 subunit of interleukin-23) with placebo in nearly 1300 patients, mirikizumab (300 mg intravenously every four weeks) resulted in higher rates of clinical remission after 12 weeks (24 versus 13 percent) [<a href="#rid11">11</a>]. In the maintenance trial including over 500 patients, mirikizumab (200 mg subcutaneously every four weeks) resulted in higher rates of clinical remission after 40 weeks (50 versus 25 percent). Based on these data, the US Food and Drug Administration approved mirikizumab for moderate to severe UC [<a href="#rid12">12</a>]. We anticipate using mirikizumab as first- or second-line therapy for adults with moderate to severe UC. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Anti-interleukin antibody-based therapy'</a>.)</p><p class="headingAnchor" id="H143327"><span class="h2">Clinical practice update on risk stratification for colorectal cancer screening and postpolypectomy surveillance (December 2023)</span></p><p>The American Gastroenterological Association (AGA) recently published nine statements of best practice advice on risk stratification for colorectal cancer (CRC) screening and postpolypectomy surveillance [<a href="#rid13">13</a>]. They advise basing risk stratification on an individual's age, a known or suspected predisposing hereditary CRC syndrome, other CRC predisposing conditions (eg, inflammatory bowel disease), and/or a family history of CRC. They also suggest that the decision to continue postpolypectomy surveillance for individuals older than 75 years should be individualized. Shared decision-making discussions should include an assessment of the risks of incident CRC, procedure-related risks, comorbidities, and life expectancy (&gt;5 years). Our approach is consistent with this guidance. (See  <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">"Overview of colon polyps", section on 'Risk assessment for subsequent colorectal cancer'</a>.)</p><p class="headingAnchor" id="H143375"><span class="h2">Investigational therapy for irritable bowel syndrome with bile acid diarrhea (November 2023)</span></p><p>Patients with irritable bowel syndrome with predominant diarrhea (IBS-D) frequently have concurrent bile acid malabsorption. In a randomized trial in which 31 patients with IBS and bile acid diarrhea were assigned to aldafermin (an investigational analogue of recombinant human fibroblast growth factor 19) or placebo for 28 days, the aldafermin group had lower bile acid synthesis and improved stool consistency during week 4 of treatment, but abdominal pain and stool frequency were not significantly different for the two groups [<a href="#rid14">14</a>]. Treatment-related adverse events were significantly higher in patients in the aldafermin group, and four patients on aldafermin had a clinically significant increase in low-density lipoprotein cholesterol. More studies are needed to clarify if aldafermin has a role in the treatment of IBS-D. (See  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults", section on 'Other therapies'</a>.)</p><p class="headingAnchor" id="H143107"><span class="h2">Low-dose tricyclic antidepressants in irritable bowel syndrome (October 2023)</span></p><p>The efficacy of tricyclic antidepressants (TCAs) in the management of irritable bowel syndrome (IBS) has not been well established in the primary care setting. In a pragmatic randomized trial, 463 patients with IBS unresponsive to dietary advice and first-line therapies in primary care practices were assigned to titrated low-dose <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> or placebo as a second-line therapy [<a href="#rid15">15</a>]. At six months, patients treated with low-dose amitriptyline had lower IBS-symptom severity scores and a higher rate of symptom relief. The most common side effects were related to the anticholinergic effects of amitriptyline, but the majority were mild. These data support current guidelines and our recommendation to use TCAs in the management of patients with IBS. (See  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults", section on 'Antidepressants'</a>.)</p><p class="headingAnchor" id="H143132"><span class="h2">Pozelimab for CD55-deficient protein losing enteropathy (October 2023)</span></p><p>Protein-losing enteropathies (PLE) are characterized by excessive loss of serum proteins into the gastrointestinal tract, resulting in hypoproteinemia, edema, and pleural and pericardial effusions. <a class="drug drug_general" data-topicid="142480" href="/z/d/drug information/142480.html" rel="external">Pozelimab</a>, a C5 inhibitor, has been approved by the US Food and Drug Administration (FDA) to treat patients with CD55-deficient PLE (CHAPLE syndrome) based on an ongoing single-arm phase II/III clinical trial of 10 patients with CHAPLE syndrome and symptomatic hypoalbuminemia [<a href="#rid16">16</a>]. All patients achieved normalization of albumin by week 12 of treatment with pozelimab and maintained serum albumin concentrations within the normal range through at least 72 weeks. Improvements were also reported in serum IgG levels and total iron-binding capacity. Although FDA approved, long-term safety data are still needed. (See  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy", section on 'Treatment of the underlying disease'</a>.)</p><p class="headingAnchor" id="H142039"><span class="h2">Guidelines on chronic idiopathic constipation (July 2023)</span></p><p>The American College of Gastroenterology and American Gastroenterological Association updated guidelines on the management of chronic idiopathic constipation (CIC) include use of fiber as first-line therapy and the use of stimulant laxatives for short-term use and rescue therapy [<a href="#rid17">17</a>]. Options for CIC refractory to over-the-counter agents include <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a>, <a class="drug drug_general" data-topicid="86369" href="/z/d/drug information/86369.html" rel="external">linaclotide</a>, <a class="drug drug_general" data-topicid="111695" href="/z/d/drug information/111695.html" rel="external">plecanatide</a>, and <a class="drug drug_general" data-topicid="83328" href="/z/d/drug information/83328.html" rel="external">prucalopride</a>. Our recommendations are largely consistent with these guidelines. (See  <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">"Management of chronic constipation in adults", section on 'Bulk-forming laxatives'</a>.)<br/></p><p class="headingAnchor" id="H85_143260"><span class="h1">OTHER GASTROENTEROLOGY AND NUTRITION</span></p><p class="headingAnchor" id="H143260"><span class="h2">Clinical practice update on bloating and distention (November 2023)</span></p><p>The American Gastroenterological Association (AGA) recently published best practice advice on the evaluation and management of bloating and distention [<a href="#rid18">18</a>]. The AGA Clinical Practice Update endorses serologic evaluation for celiac disease and exclusion of carbohydrate enzyme deficiencies with dietary restriction and/or breath testing, but emphasizes reserving additional evaluation with abdominal imaging and upper endoscopy for patients with alarm features, recent worsening symptoms, or an abnormal physical examination. Our approach is consistent with this guidance. (See  <a class="medical medical_review" href="/z/d/html/2607.html" rel="external">"Overview of intestinal gas and bloating", section on 'Evaluation'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rughwani H, Singh AP, Ramchandani M, et al. A Randomized, Controlled Trial Comparing the Total Enteroscopy Rate and Diagnostic Efficacy of Novel Motorized Spiral Enteroscopy and Single-Balloon Enteroscopy in Patients With Small-Bowel Disorders: The Motor Trial (NCT 05548140). Am J Gastroenterol 2023; 118:1855.</a></li><li><a class="nounderline abstract_t">Chen J, Guo Y, Huang Y, et al. Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial. J Infect Dis 2023; 228:511.</a></li><li><a class="nounderline abstract_t">Kann AE, Jepsen P, Madsen LG, et al. Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study. Lancet Gastroenterol Hepatol 2023; 8:1028.</a></li><li class="breakAll">Improvements to MELD, PELD, Status 1A and Status 1B to take effect July 13. United Network for Organ Sharing, 2023. Available at: https://unos.org/news/improvements-to-meld-and-peld-phase-1-data-entry-in-effect-june-15/ (Accessed on September 04, 2023).</li><li><a class="nounderline abstract_t">Patel N, Silvey S, O'Leary JG, et al. Early paracentesis is associated with better prognosis compared with late or no-paracentesis in hospitalized veterans with cirrhosis and ascites. Liver Transpl 2023; 29:919.</a></li><li><a class="nounderline abstract_t">Zhao L, Zhang X, Coday M, et al. Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality. JAMA 2023; 330:537.</a></li><li><a class="nounderline abstract_t">D'Antiga L, Beuers U, Ronzitti G, et al. Gene Therapy in Patients with the Crigler-Najjar Syndrome. N Engl J Med 2023; 389:620.</a></li><li><a class="nounderline abstract_t">Marchegiani G, Pollini T, Burelli A, et al. Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation. Gastroenterology 2023; 165:1016.</a></li><li><a class="nounderline abstract_t">Bergman D, Roelstraete B, Olén O, et al. Microscopic Colitis and Risk of Incident Acute Pancreatitis: A Nationwide Population-Based Matched Cohort Study. Am J Gastroenterol 2023; 118:2041.</a></li><li><a class="nounderline abstract_t">Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology 2023; 165:1292.</a></li><li><a class="nounderline abstract_t">D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388:2444.</a></li><li class="breakAll">Mirikizumab. United States Prescribing Information. Revised November, 2023. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761279s000lbl.pdf (Accessed on November 20, 2023).</li><li><a class="nounderline abstract_t">Issaka RB, Chan AT, Gupta S. AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review. Gastroenterology 2023; 165:1280.</a></li><li><a class="nounderline abstract_t">BouSaba J, Torres M, Dilmaghani S, et al. Effects of FGF19 Analogue Aldafermin in Patients With Bile Acid Diarrhea: A Randomized, Placebo-Control Trial. Gastroenterology 2023; 165:499.</a></li><li><a class="nounderline abstract_t">Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials 2022; 23:552.</a></li><li class="breakAll">U.S. Food and Drug Administration. FDA approves first treatment for CD55-deficient protein-losing enteropathy (CHAPLE disease). Available at https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-cd55-deficient-protein-losing-enteropathy-chaple-disease (Accessed on October 23, 2023).</li><li><a class="nounderline abstract_t">Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Am J Gastroenterol 2023; 118:936.</a></li><li><a class="nounderline abstract_t">Moshiree B, Drossman D, Shaukat A. AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review. Gastroenterology 2023; 165:791.</a></li></ol></div><div id="topicVersionRevision">Topic 8351 Version 12473.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37463435" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A Randomized, Controlled Trial Comparing the Total Enteroscopy Rate and Diagnostic Efficacy of Novel Motorized Spiral Enteroscopy and Single-Balloon Enteroscopy in Patients With Small-Bowel Disorders: The Motor Trial (NCT 05548140).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37079894" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37660703" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37660703" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36971257" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early paracentesis is associated with better prognosis compared with late or no-paracentesis in hospitalized veterans with cirrhosis and ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37552302" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37585628" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gene Therapy in Patients with the Crigler-Najjar Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37406887" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37171015" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Microscopic Colitis and Risk of Incident Acute Pancreatitis: A Nationwide Population-Based Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37737818" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37379135" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37379135" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37737817" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37084852" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of FGF19 Analogue Aldafermin in Patients With Bile Acid Diarrhea: A Randomized, Placebo-Control Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35804433" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35804433" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37204227" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37452811" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
